Dual benefit of supplementary oral 5‐aminolevulinic acid to pelvic radiotherapy in a syngenic prostate cancer model
Authors:
- 18 November 2018
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 79 (4) , 340-351
Abstract
Background: Normal tissue damage caused by radiotherapy remains the largest dose‐limiting factor in radiotherapy for cancer. Therefore, the aim of this study was to investigate the supplementary oral 5‐aminolevulinic acid (ALA) to standard radiation therapy as a novel radioprotective approach that would not compromise the antitumor effect of radiation in normal rectal and bladder mucosa in a syngenic prostate cancer (PCa) model.Methods: To evaluate the radiosensitizing effect of ALA in vitro, clonogenic survival assays were performed in DU145, PC3, and MyC‐CaP cell lines. To evaluate the effect of ALA in vivo a single dose (25 Gy) of radiation with or without ALA was given to healthy mice. Next, a syngenic PCa model of MyC‐CaP cells in FVB mice was created, and multiple doses (12 Gy total) of radiation were administered to the mouse pelvic area with or without ALA administration. Resected tumors, recta, and urinary bladders were immunostained with antibodies against Ki‐67, γ‐H2AX, CD204, and uroplakin‐III. Total RNA levels in recta and urinary bladders were analyzed via RT2 Profiler polymerase chain reaction (PCR) arrays related to “Stress & Toxicity PathwayFinder,” “Mitochondria,” and “Inflammasomes.”Results: The addition of in vitro single or in vivo repeated administration of exogenous ALA acted as a radiosensitizer for PCa cells. Rectal toxicity was characterized by histological changes including loss of surface epithelium, fibrosis, severe DNA damage, and the aggregation of M2 macrophages. Urinary bladder toxicity was characterized by bladder wall thickening and urothelium denuding. The higher dose (300 mg/kg/day) of ALA exerted a better radioprotective profile than the lower dose (30 mg/kg/day) in normal recta and urinary bladders. Out of the 252 genes tested, 35 (13.4%) were detected as relevant genes which may be involved in the radioprotective role of ALA administration. These included interleukin‐1a (IL‐1a), IL‐1b, IL‐12, chemokine (C‐X‐C motif) ligand 1 (CXCL1), CXCL3, and NLRP3.Conclusions: Our study provides novel and comprehensive insights into the dual benefits including radiosensitizing PCa tumor tissues and radioprotection of normal pelvic organs from radiation therapy. Knowledge of the underlying mechanism will facilitate the search for optimal treatment parameters for supplemental oral ALA during radiotherapy for PCa.Keywords
Funding Information
- Nara Medical University Grant-in-Aid for Collaborative Research Projects (Fiscal Years 2015-2016)
This publication has 32 references indexed in Scilit:
- 5-Aminolevulinic acid combined with ferrous iron induces carbon monoxide generation in mouse kidneys and protects from renal ischemia-reperfusion injuryAmerican Journal of Physiology-Renal Physiology, 2013
- Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapyRadiation Oncology, 2013
- In vivo multiphoton imaging of mitochondrial structure and function during acute kidney injuryKidney International, 2013
- Irradiation Promotes an M2 Macrophage Phenotype in Tumor HypoxiaFrontiers in Oncology, 2012
- Functional Outcomes and Complications Following Radiation Therapy for Prostate Cancer: A Critical Analysis of the LiteratureEuropean Urology, 2012
- siRNA‐mediated Knockdown of the Heme Synthesis and Degradation Pathways: Modulation of Treatment Effect of 5‐Aminolevulinic Acid‐based Photodynamic Therapy in Urothelial Cancer Cell LinesPhotochemistry and Photobiology, 2009
- Radiation-induced damage to mouse urothelial barrierRadiotherapy and Oncology, 2006
- Heme oxygenase-1: A provenance for cytoprotective pathways in the kidney and other tissuesKidney International, 2006
- Context-Dependent Hormone-Refractory Progression Revealed through Characterization of a Novel Murine Prostate Cancer Cell LineCancer Research, 2005
- Evaluation of Tempol Radioprotection in a Murine Tumor ModelFree Radical Biology and Medicine, 1997